About Advanced Microbiome Interventions - AMI-Pharma

Advanced Microbiome Interventions (AMI) is an Amsterdam-based biotech company focusing on developing single oral dose treatments for Type 1 Diabetes (T1D) and other Auto-Immune Diseases (AIDs). AMI is capitalizing on the patented discoveries of its founders with advanced knowledge of microbiome development and business.

Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. Type 1 diabetes (T1D), is a chronic condition in which the pancreas produces little or no insulin by itself. T1D is an autoimmune diseases (AID) - other AIDs include atopic dermatitis, celiac disease, rheumatoid arthritis, thyroid disease, and inflammatory bowel disease, such as ulcerative colitis and Crohn’s disease.

About 24 million (~7.5%) people in the United States are affected by an AID with women more commonly affected than men. AIDs are common, with an estimated prevalence of 3,225/100,000. The total global market of AID therapeutics  is expected to increase to 185 B$ in the next ten years*.

* data from www.ihealthcareanalyst.com

The AMI pipeline consists of a series of microbiome-based strains, metabolites and related compounds that are purified and developed for the indications shown.